spacer
home > ebr > spring 2009 > european biotechnology on the world stage
PUBLICATIONS
European Biopharmaceutical Review

European Biotechnology on the World Stage

 

THE WORLD STAGE

European biotechnology on the world stage plays a major role as an innovator in new startups and in translating Europe’s continuing strength in research into a commercial context. Since the explosion of commercial biotechnology in Europe in the 1990s, the sector has strived to follow in the footsteps of the US in creating valuable, fast growing companies that feed the ever-hungry pipelines of the productstarved pharma companies.

However, Europe has not managed to recreate the American model on this side of the Atlantic, and holds a different place in the biotechnology world. Whilst it is true that Europe creates a comparable number of new biotechs each year to the US, few achieve the size and maturity of US companies. This may be for a number of reasons.

European Late Starter?

The boom in the biotech sector in Europe occurred after the US and many companies failed to reach critical mass and maturity before the funding crash of 2001. The era of ‘if it moves, invest in it’ is unlikely to be seen again, and only those companies that achieved a solid pipeline were able to generate significant funding.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Dr Claire Skentelbery is the network Manager for the Council of European BioRegions (CEBR). Based in Brussels, Claire has worked within the biotech sector since completing her PhD. Claire has focused on the communication and networking of biotechnology throughout her career, including technical and promotional writing, national contact point for biotech in the UK in FP5, international event management and network management. She currently has two jobs: she works as the Network Manager for the Council of European BioRegions, and is also Biotechnology Strategic Adviser for Europe Unlimited, a Brussels-based company that brings together the value chain, from research to end-use, for high-tech companies to accelerate investment.

spacer
Claire Skentelbery
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

High Throughput Analytics Herald a Paradigm Shift in the Development of Biopharmaceuticals

Heilbronn/Dortmund August 2019: Biopharmaceuticals have revolutionized therapies of various diseases. In particular with regard to chronical and/or severe clinical conditions like multiple sclerosis, rheumatoid arthritis or cancer they are considered the future of treatment. Also economically biological drugs are on their way up: The global biopharmaceuticals market is anticipated to reach about 400 billion USD by 2025. Which strategic alignment will help best to fill a successful pipeline?
More info >>

White Papers

Blockbuster Drugs Need Blockbuster Components

West Pharmaceutical Services, Inc.

Many of the world’s blockbuster drugs are now delivered via a prefilled syringe system or auto-injector. To ensure patient safety, pharmaceutical manufacturers need high-quality components that feature reduced particulates and ensure consistency of delivery while fitting the changing needs of higher-volume delivery systems.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement